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Abstract
Findings: We set out to analyse the gene expression profile of pre-osteoblastic C2C12 cells during
osteodifferentiation induced by both rhBMP2 and rhBMP7 using DNA microarrays. Induced and repressed genes
were intercepted, resulting in 1,318 induced genes and 704 repressed genes by both rhBMP2 and rhBMP7. We
selected and validated, by RT-qPCR, 24 genes which were upregulated by rhBMP2 and rhBMP7; of these, 13 are
related to transcription (Runx2, Dlx1, Dlx2, Dlx5, Id1, Id2, Id3, Fkhr1, Osx, Hoxc8, Glis1, Glis3 and Cfdp1), four are
associated with cell signalling pathways (Lrp6, Dvl1, Ecsit and PKCδ) and seven are associated with the extracellular
matrix (Ltbp2, Grn, Postn, Plod1, BMP1, Htra1 and IGFBP-rP10). The novel identified genes include: Hoxc8, Glis1, Glis3,
Ecsit, PKCδ, LrP6, Dvl1, Grn, BMP1, Ltbp2, Plod1, Htra1 and IGFBP-rP10.
Background: BMPs (bone morphogenetic proteins) are members of the TGFb (transforming growth factor-b)
super-family of proteins, which regulate growth and differentiation of different cell types in various tissues, and
play a critical role in the differentiation of mesenchymal cells into osteoblasts. In particular, rhBMP2 and rhBMP7
promote osteoinduction in vitro and in vivo, and both proteins are therapeutically applied in orthopaedics and
dentistry.
Conclusion: Using DNA microarrays and RT-qPCR, we identified both previously known and novel genes which are
upregulated by rhBMP2 and rhBMP7 during the onset of osteoblastic transdifferentiation of pre-myoblastic C2C12
cells. Subsequent studies of these genes in C2C12 and mesenchymal or pre-osteoblastic cells should reveal more
details about their role during this type of cellular differentiation induced by BMP2 or BMP7. These studies are
relevant to better understanding the molecular mechanisms underlying osteoblastic differentiation and bone
repair.
Background
Bone formation and fracture repair depends on the
expression and action of the bone morphogenetic pro-
teins (BMPs), which are members of the transforming
growth factor beta (TGF-beta) superfamily of dimeric,
disulphide-linked growth factors, comprising more than
15 related proteins. In addition to a crucial role in
osteogenesis, BMPs display a myriad of roles in cell pro-
liferation, differentiation, migration and apoptosis, in
different cell types [1]. Their role is essential at early
phases of development and organogenesis, such as axial
embryo determination [2], as well as in limb, eye and
kidney development, such that ablation of these genes
results in death at very early stages of development, as
observed in knock-out mice [3]. In humans, recombi-
nant BMP2 and BMP7 have gained attention in bone
repair and in non-union spinal fractures due to their
capacity to stimulate the differentiation of mesenchymal
stem cells from the periosteum near the lesion site after
migration and proliferation induced by IL-1, IL-6, and
TNF-a [4]. This feature was first observed in the 1960s
through the ectopic bone formation activity induced by
bone extracts [5]. However, since only a few clinical
trials concerning the use of these proteins are available,
questions about the amount of BMPs required for
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complete bone regeneration and the extent of side
effects caused by their application remains unclear.
BMPs can activate osteoblastic differentiation by bind-
ing to two different surface receptor classes on the cells,
namely: type I receptors or activin receptor-like kinases
(Alk 2, 3 and 6) and type II receptors (BMPR2 and acti-
vin A receptors type IIA and IIB), which are constitu-
tively active, and transfer a phosphoryl group to serine
and threonine residues in type I receptors upon ligand
binding. Nevertheless, this binding is specific for each
type of BMP, since BMP2 displays higher affinity for the
Alk2 and Alk3 receptors, whereas BMP7 has more affi-
nity for Alk2 receptors [6]. In addition, the downstream
signalling pathway depends on how these receptors are
disposed. When the receptors are already dimerised
(PFC; pre-formed complex) prior to BMP binding, the
Smad downstream pathway is activated through the
Smad proteins 1, 5 and 8, which activate Runx2, Dlx5
and Osterix (Osx). In the BMP-induced signalling com-
plex (BISC), BMP binding leads to receptor dimerisa-
tion; the caveosome-directed pathway leads to MAPK
activation, which leads to an induction of RunX2
expression and phosphorylation, thus determining osteo-
blastic differentiation [1]. Moreover, in vitro studies have
shown activation of the Osx proteins in Smad knock-
down cell lines, indicating independent MAPK-activated
osteoblastic differentiation. On the other hand, ERK1/2
has been found to inhibit Smad and halt bone formation
[7]. These findings suggest that osteoblastic differentia-
tion is a time-dependent process, involving the activa-
tion and inhibition of different substrates and
expression of different types of genes whose nature
remains to be elucidated. To investigate the transcrip-
tional events which are independently regulated by
BMP2 and BMP7, we used a gene expression microarray
platform containing DNA sequences corresponding to
36,000 genes and RT-qPCR to examine the expression
of early genes during osteogenic transdifferentiation in
pre-myoblastic C2C12 cells, upon induction by rhBMP2
or rhBMP7. This effort resulted in the assessment of
both previously known and novel genes which are com-
monly activated by both rhBMPs.
Material and methods
Cell Culture
The mouse pre-myoblastic and pre-osteoblastic C2C12
cell line was obtained from the American Type Culture
Collection. These cells were maintained in DMEM
(Gibco BRL, Gaithersburg, MD, USA) containing 10%
FBS (HyClone®) and antibiotics (100 U/ml of penicillin-
G and 100 mg/ml of streptomycin, GIBCO) at 37°C in a
humidified atmosphere of 2.5% CO2 in air. For differen-
tiation experiments, cells were seeded at a density of 2
× 104 cells/cm2 and grown for 24 h. Subsequently, the
medium was replaced by DMEM containing 5% FBS in
the presence or absence of 200 ng/ml rhBMP2 or 200
ng/ml rhBMP7 (R&D Systems Inc., Minneapolis, MN).
The activity of rhBMP2 and rhBMP7 was determined by
the alkaline phosphatase activity assay in C2C12 cells.
RNA isolation and DNA microarray hybridisation
C2C12 cultures were collected after 0, 4, 8, 12 and 24h
of treatment with rhBMP2 or rhBMP7 for extraction of
total RNA using the RNeasy kit (Qiagen, Hilden, Ger-
many). Each cRNA was prepared as recommended in
the Amersham CodelinkTM iExpress Assay Reagent Kit
manual. Briefly, the samples containing 1.5 μg RNA of
each culture treated for 12 h with each rhBMP (2 and
7) were mixed with 7.5 ml of bacterial mRNAs (10 pg/
μl) and 1 μl of oligo dT to a final volume of 12 μl. Each
reaction was incubated at 70°C for 10 min and kept on
ice for 3 min. Subsequently, 2 μl of 10X First Strand
Buffer, 4 μl of 5 mM dNTPs, 1 μl of RNase inhibitor
and 1 μl of ArrayScript were added to each tube, to a
final volume of 20 μl. Each reaction was incubated at
42°C for 2 h. After this period, each tube was placed on
ice and 63 μl of water, 10 μl of 10X second strand buf-
fer, 4 μl of 5 mM dNTPs, 2 μl of DNA polymerase and
1 μl of RNaseH were added to each tube. After incubat-
ing the reactions at 16°C for 2 h, each cDNA was puri-
fied and 20 μl of each purified cDNA was mixed with
12 μl biotin-NTP, 4 μl of 10X T7 reaction buffer and 4
μl of 10X enzyme mix reaction buffer, then incubated at
37°C for 14 h. After cRNA synthesis, each cRNA pre-
paration was purified and 10 μg of each biotinylated
cRNA was mixed with 5 μl of fragmentation buffer in a
final volume of 25 μl, incubated at 94°C for 20 min and
then kept on ice for 5 min. Subsequently, 25 μl of each
reaction was transferred to another tube containing 78
μl of hybridisation buffer A, 130 μl of hybridisation buf-
fer B and 27 μl of water; the reaction was incubated at
90°C for 5 min. Each tube was then placed on ice and
applied to the Codelink DNA microarray containing
around 36,000 genes. The subsequent stages of hybridi-
sation, washing and analysis of each microarray were
carried out as detailed in the Codelink Gene Expression
System: Single-Assay Bioarray Hybridisation and Detec-
tion manual.
DNA microarray analysis
The gene expression data were normalised using the
SVR (Support Vector Regression) method [8], imple-
mented in the GEDI toolbox [9]. More information on
normalisation method is available at http://mariwork.
iq.usp.br/gedi/. Briefly, SVR is a non-parametric regres-
sion, similar to the Loess method; however, it has
greater accuracy than the Loess method, therefore, it is
a more useful tool to identify differentially expressed
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genes. Identification of these genes was obtained using
the ratio of normalised intensities between rhBMP (2
or 7) and control (untreated) samples, considering a
fold change of ≥ 2.5. Induced and repressed genes
in C2C12 cells under simultaneous treatment
with rhBMP2 and rhBMP7 were classified according
to their functions through the FatiGO program
(http://bioinfo.cipf.es/babelomicswiki/tool:fatigo).
Real Time RT-PCR
One microgram of total RNA was treated with 1 U of
DNaseI at 37°C for 20 min and at 75°C for 10 min. The
RT reaction was carried out at 50°C for 2 h in a 20 μl mix
of 1X first strand buffer, 10 mM DTT, 2.5 mM of poly-dT
primer (Amersham-Bioscience), 1 mM each of dNTPs, 20
U of RNAseOUT (Invitrogen) and 20 U of Superscript III
(Invitrogen). The mixture was then incubated at 70°C for
15 min and incubated with 5 U of RNaseH at 37°C for 30
min and finally incubated at 75°C for 10 min. Samples of
cDNA were diluted to 100 μl, and 3 μl aliquots of this
cDNA solution were used for quantitative PCR using a
Light-Cycler Real Time PCR System 7300 (Applied Biosys-
tems). The PCR reaction was carried out in a 12 μl mix
containing 6 μl of Sybr®Green Mastermix (Applied Biosys-
tems), 3 μl of the cDNA solution and 3 μl of the appropri-
ate primers in a concentration between 200 to 600 nm
under the following conditions: 2 min at 50°C, 10 min at
95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at
60°C. Expression values were calculated from threshold
cycle at which an increase in reporter fluorescence above
baseline signal could first be detected (CT). For data nor-
malisation, three housekeeping genes were used, namely
mGAPDH, mHPRT and mHMBS, using a calculated factor
that was generated by the GeNorm program [10]. Control
(untreated) and rhBMP2 and rhBMP7 treated groups were
compared using a two-way ANOVA (Bonferroni test) and
the GraphPad Prism 4 program. All primers used (Table
1) were validated beforehand according to the method
described by Rasmussen [11].
Protein network analysis of gene products which were
upregulated by treatment with rhBMP2/7
Accession numbers for genes validated by real-time RT-
PCR were searched against the STRING database ver-
sion 9 (http://string-db.org/) [12] for protein-protein
interactions, using a STRING confidence score set to ≥
0.7 (high confidence).
Results
Gene expression profiles during osteodifferentiation of
C2C12 cells induced by rhBMP2 and rhBMP7 were
constructed using DNA microarrays
In order to identify novel potential regulators of osteo-
blastic differentiation, we used DNA microarrays and
RT-qPCR. Total RNA was isolated after 12 h of treat-
ment with rhBMP2 or rhBMP7 for both DNA microar-
ray and RT-qPCR experiments. In addition, total RNA
was collected at 0, 4, 8 and 24h after stimulation with
each of these BMPs for RT-qPCR analysis. Upon treat-
ment of C2C12 cells with rhBMP2 or rhBMP7, the
microarray analysis data resulted in 1,862 and 2,517
upregulated genes, and 1,335 and 1,918 downregulated
genes, respectively, considering as significant a fold
change of 2.5-fold or higher. Induced and repressed
genes were intercepted, resulting in 1,318 induced genes
and 704 repressed genes by both rhBMP2 and rhBMP7.
The differentially expressed genes regulated in com-
mon by rhBMP2 and rhBMP7 were classified according
to their function, as predicted by the FatiGO Data
Mining program (http://bioinfo.cipf.es/babelomicswiki/
tool:fatigo), which classifies genes according to Gene
Ontology (GO) criteria (cellular component, function
and molecular biological process), thereby allowing the
selection of 24 genes induced by both rhBMP2 and
rhBMP7. These genes, which are related mainly to signal
transduction, development, cell differentiation, osteodif-
ferentiation and bone repair, are shown in Table 2, with
the fold change for each gene also being shown.
Differential gene expression was validated by RT-
qPCR. The results represent the mean values of three
independent experiments, each of which was performed
in triplicate. The relative expression of each gene was
calculated as described in the Materials and Methods.
Figure 1 shows the expression profile of 13 genes
involved in the transcriptional regulation of several
genes, some of which are already known to be involved
in the regulation of different cellular processes, while
others have not yet been characterised, namely: Runx2,
Dlx1, Dlx2, Dlx5, Id1, Id2, Id3, Fkhr1, Osx, Hoxc8, Glis1,
Glis3 and Cfdp1. Id1, Id2 and Id3 correspond to pro-
teins which bind to transcription factors, modifying
their ability to bind DNA and affecting the expression
of one or more genes. Cfdp1 could participate in the
complex of proteins that modify the chromatin state,
thus regulating the transcription of several genes. All of
the other genes presented in Figure 1 code for transcrip-
tion factors. The first gene is the well-known Runx2,
which was induced to similar levels by rhBMP2 and
rhBMP7. Runx2 was upregulated four hours after treat-
ment, and the highest level of expression appeared 12 h
after treatment, declining at 24 h, but remaining signifi-
cantly higher than the control. This same expression
profile was observed for Id1, Id2 and Id3, but, in the
case of Id2, treatment with rhBMP7 caused a higher
level of expression than rhBMP2 at 4, 8, 12 and 24 h;
for Id1 and Id3, there was also a difference in induction
over these time periods, but it was lower than that
achieved by Id2. Dlx1 and Dlx2 were induced 4 h after
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stimulation with both rhBMPs. Dlx1 reached its maxi-
mum expression 12 h after treatment, then decreased to
basal levels by 24 h. During this period of time, Dlx2
reached its highest expression level. Dlx5 was similarly
upregulated by both rhBMPs, with a slight increase
between 4-8 h and a further increase (5 to 6-fold) at 12
and 24 h. Fkhr1 was induced, displayed its maximum
expression level after 4 h and decreased thereafter to
basal levels at 24 h. The expression of Osx began to
increase 4 h after treatment and gradually increased
until reaching its maximum level after 24 h; expression
levels were similar upon treatment with both proteins.
Hoxc8 expression slightly increased after 4 and 8 h,
reached its maximum level at 12 h and decreased at 24
h after treatment with rhBMP2, while treatment with
rhBMP7 caused increased expression only at 12 and 24
h. Another difference was that, after 12 h of treatment,
rhBMP2 caused greater expression of Hoxc8 than
rhBMP7. Glis1 was upregulated at 4 h, and remained at
a constant level for up to 12h, decreasing at 24 h, but,
in this case, there was a clearly greater increased expres-
sion when C2C12 cells were treated with rhBMP2 than
with rhBMP7. Glis3 was induced after 4 h of treatment,
remained constant for up to 12 h and decreased at 24h,
but, unlike Glis1, the level of expression achieved by
Glis3 was very similar in cells treated with rhBMP2 or
rhBMP7.
The differential expression of the Cfdp1 gene is shown
in Figure 1. This gene was induced by rhBMP2 at 4 h,
was maintained at a constant expression level for up to
8 h, slightly increased at 12 h and decreased again at 24
h to similar levels as those detected at 4 or 8 h. On the
other hand, the expression of Cfdp1 only significantly
increased 12 h after treatment with rhBMP7 but by 24 h
was expressed at a higher level when compared to
control.
Figure 2 shows the expression analysis of genes related
to cell signalling: Lrp6, Dvl1, Ecsit and PKCδ. The
expression of Lrp6 slightly increased after 4 and 8 h of
treatment with rhBMPs, then reached maximum expres-
sion levels at 12 h and decreased by 24h. Treatment
with rhBMP7 caused a slight increase in Dvl1 expression
at 8 h while rhBMP2 did not generate such a response.
Coincidentally, maximum expression was found at 12 h
in cells treated with both recombinant proteins, with
slightly decreasing levels until up to 24h. The expression
Table 1 RT-PCR primers used in this study
Gene Forward Reverse
mG3PDH GATGCCCCCATGTTTGTGAT GGTCATGAGCCCTTCCACAAT
mHMBS GCGGAAGAAAACGGCTCAA TCCCGTGGTGGACATAGCA
mHPRT GTCCCAGCGTCGTGATTAGC TCATGACATCTCGAGCAAGTCTTT
Runx2 ACCGAGACCAACCGAGTCAT CTCGGATCCCAAAAGAAGCTT
Dlx1 GTCTGTGCGCCGAAGTCAA GCCCGGAAGAAGACCATTC
Dlx2 CAGCGGCCTCAACAATGTCT ATTCGGATTTCAGGCTCAAGGT
Dlx5 GCCTCTCTAGGACTGACGCAAA TGGTGACTGTGGCGAGTTACA
Id1 GATGGACTCCAGCCCTTCAG TGGAGAGGGTGAGGCTCTGT
Id2 GGTGGACGACCCGATGAGT GCGATCTGCAGGTCCAAGAT
Id3 GAAATCCTGCAGCGTGTCATAG AAAGCTCCTCTTGTCCTTGGAGAT
Osx TCCCCTTGTCGTCATGGTTAC TTGAATTTGATCCCAGAGAAAGC
Hoxc8 ATGCCCAGCATACACTCTCTTGT ATAAATACCAGAGAAGCACCGTGAA
Fkhr1 CCTTTGCCCCAGATGCCTAT GGGATCAACCGGTGACATAATG
Glis1 AGAAGCCCAACAAGTGCATGTT GGTCGCTGGAGTTGCTGAAG
Glis3 TGCACCTCTTCCATCTTCTCATT TTCCCGTTCTTGTGCATATTCAT
Cfdp1 AAGAAGGGTACATTGAGCGGAAA AGGAGCTCACATTGTCAATAGGATT
Lrp6 ACCAAGGTCCAGGCTCGAA GCATCTTGTCGTACCATCTCCTTT
Dvl1 AAGAGTGACATGAGTGCCATTGTC GAAGCCCTCCACGTGTGTGTA
Ecsit AAGCTGTGGTTCACCCGATTC GGGCAAAGACATCTGGTAGACAGT
Pkcd GTGGTGTTGATTGACGATGATGTAG ACCCCCATTGAGAAACTCCAT
Ltbp2 AGGAGCCAAGAGTTAAAGAAATCTAAAA TTTCCCATAGGATAGATGTGCCTAA
Grn CAATGCCCAATGCCATCTG ACTTCACCTCCTTCACTGGGTATC
BMP1 CCATGTCTCTATTGTACGCGAGAA AAGATGCCCCTGGAGAATGTG
Plod1 AAACGTGCCCACTATCGACAT CGGACGACGAAGGCTAGATC
Postn TTAGCATCTTCCTCAGCCTCCTT GAGCATTTTTATCCCCAATCAGAA
Htra1 AGCTGAGACCTGGAGAATTTGTAGTT TAGCGTCTGTCTGAATGTAGTCCAT
IGFBP-rP10 GCTGCAATCACGGAGTTTGTT GTCTTCTCCGGGCTTTCTACAC
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of Ecsit increased 4 h after stimulation, slightly
decreased at 8 h increased again at 12 h and decreased
to basal levels at 24 h. In the case of PKCδ, treatment
with rhBMP2 for 4 h caused greater expression when
compared to treatment with rhBMP7. However, at 8
and 12 h, the levels achieved with both treatments were
very similar. Finally, at 24 h, greater expression was
found in cells treated with rhBMP2, when compared to
the control and to treatment with rhBMP7, but the
expression of this gene decreased at this time point.
Upon analysis of the DNA microarrays, seven genes
related to the extracellular matrix were selected to be
examined by RT-qPCR, namely Ltbp2, Grn, Postn,
Plod1, BMP1, Htra1 and IGFBP-rP10; the results are
shown in Figure 3. The expression of Ltbp2 increased
upon BMP stimulation 4 h after treatment, maintained a
constant level of expression for up to 12 h, but
decreased after 24 h. As can be observed, slightly higher
expression was found in cells were treated with rhBMP2
compared to cells treated with rhBMP7. A similar
expression profile was found for Grn, Postn, Plod1 and
BMP1. Coincidentally, increased expression of these
four genes occurred after 12 h of stimulation with
rhBMP2 and rhBMP7 and continued to increase at 24
h. Upon incubation with both rhBMPs, the expression
of Htra1 began to gradually increase at 4 h, was main-
tained at this level at 8 h, reached a peak at 12 h and
fell to basal levels at 24 h. As can be seen in Figure 3,
the expression of IGFBP-rP10 was induced at 4 h after
treatment and remained at a constant level at 8 h and
increased again at 12 h, with higher levels in cells incu-
bated with rhBMP2 than with rhBMP7. At 24 h, the
level of expression induced by rhBMP2 was very similar
to that obtained at 12 h, or remained virtually the same,
except for the fact that the expression induced by
rhBMP7 at 24 h was about twice the level seen at 12 h.
Discussion
Our DNA microarray analysis refers to treatment of
pre-myoblastic and pre-osteoblastic C2C12 cells with
BMP2 and BMP7 for a period of 12 h. The choice of
this period relies on the fact that expression of the
genes which induce C2C12 cells to differentiate into
osteoblast-like cells is found upon treatment with
rhBMP2 for 8 and 16 h [13]. The cut-off of 2.5-fold
change was chosen due to the fact that Runx2, which is
widely known to be activated by both rhBMPs during
osteodifferentiation [14], presented a fold change of 2.94
Table 2 Genes selected by DNA microarray analysis during osteodifferentiation of C2C12 cells induced by both
rhBMP2 and rhBMP7
Accession Number Gene Fold Change
rhBMP2/C rhBMP7/C
NM_009820.1 Runt related transcription factor 2 (Runx2) 2.9 3.2
NM_010495.1 Inhibitor of DNA binding 1 (Id1) 20.4 31.7
NM_010496.2 Inhibitor of DNA binding 2 (Id2) 5.8 88.3
NM_008321.1 Inhibitor of DNA binding 3 (Id3) 3.6 4.09
NM_010053.1 Distal-less homeobox 1 (Dlx1) 6.5 8.0
NM_010054.1 Distal-less homeobox 2 (Dlx2) 3.2 5.6
NM_010056.2 Distal-less homeobox 5 (Dlx5) 4.2 4.5
NM_130458.1 Osterix transcription factor (Osx) 3.7 5.5
NM_010466.1 Homeobox C8 (Hoxc8) 2.5 4.2
NM_147221.1 GLIS family zinc finger 1 (Glis1) 176.8 131.3
NM_175459.3 GLIS family zinc finger 3 (Glis3) 35.5 33.3
AF114258.1 Forkhead protein 1 (FKHR1) 3.2 67.2
NM_011801.1 Craniofacial development protein 1 (Cfdp1) 4.3 46.3
NM_010091.3 Dvl1 4.3 160.2
NM_011103.1 Protein kinase C, delta (Prkcd) 2.5 11.2
NM_012029.1 Signalling Intermediate in Toll pathway-evolutionarily conserved (Ecsit) 2.9 12.8
NM_008175.2 Granulin (Grn) 3.1 89.0
NM_008514.1 Low density lipoprotein receptor-related protein 6 (Lrp6) 2.7 6.5
NM_013589.1 Latent transforming growth factor beta binding protein 2 (Ltbp2) 5.3 17.6
NM_178929.2 Kazal-type serine protease inhibitor domain 1 (IGFBP-rP10) 3.3 7.1
NM_015784.1 Periostin, osteoblast specific factor (Postn) 2.5 14.3
NM_019564.1 High Temperature requirement 1 (Htra1) 2.5 3.9
NM_009755.2 Bone morphogenetic protein 1 (Bmp1) 4.1 55.4
NM_011122.1 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (Plod1) 37.9 45.9
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Figure 1 Relative expression levels of genes related to transcription in C2C12 cells treated with rhBMP2 and rhBMP7. Cells were
seeded and grown for 24 h at which point the medium was replaced by DMEM containing 5% FCS in the presence or absence of rhBMP2 (200
ng/ml) or rhBMP7 (200 ng/ml). RNA was isolated 0, 4, 8, 12 and 24h after stimulation. Subsequently, expression levels were measured by
quantitative real time RT-PCR. The asterisks correspond to the statistical analysis (two-way ANOVA, Bonferroni test) between control and
treatment (*p < 0.05; **p < 0.01; ***p < 0.001).
Bustos-Valenzuela et al. BMC Research Notes 2011, 4:370
http://www.biomedcentral.com/1756-0500/4/370
Page 6 of 15
and 3.17 upon treatment with rhBMP2 and rhBMP7,
respectively (Table 2). Although downregulated genes are
also of interest, they were not selected due to the fact that,
in C2C12 cells, most of these genes would probably be
more directly involved in myogenesis rather than in osteo-
genesis, but this does not rule out the interest in their ana-
lysis in future research. Therefore, our main interest was
focused on genes which are upregulated by both rhBMPs
and that could be involved in osteodifferentiation. Particu-
larly, we focused on genes which are induced at the very
beginning of osteoblast differentiation, which encompasses
the first 24 h following BMP receptor activation, a period
in which the key process for commitment to the osteoblast
lineage occurs in precursor cells.
The genes selected from the microarray analysis were
classified according to their function, 13 of which are
involved in transcription, four in cell signalling and
seven are related to the extracellular matrix. The mRNA
levels of their corresponding genes, determined by qRT-
PCR, were analysed at different time points (0, 4, 8, 12
and 24h) following treatment with both BMPs, each dis-
playing its own expression profile, which was compared
to that of the other.
Transcription factors and related proteins
Most biological processes, including osteoblastic differ-
entiation, are dependent upon transcriptional activation
of several effector genes. The signal generated upon
interaction between BMPs and their receptors causes
activation and repression of a number of genes coding
for transcription factors and, also, for proteins, which
bind to these factors, thereby positively or negatively
modifying their function. The expression profile of 13
genes related to transcription was examined by RT-
qPCR (Figure 1).
Runx2
As expected, Runx2 was induced upon 4 h of treatment
with both rhBMPs. This gene is at the end of the Smad
protein pathway, and, as recently found [7], the MAPK
pathway. As such, its product is a very important tran-
scription factor for both chondrogenesis and osteogen-
esis during the development of the skeleton [14]. In
addition to BMPs, Runx2 is also induced by TGFb and
FGF2, which are also known to be involved in bone for-
mation [15]. Runx2-/- knock-out mice show a complete
lack of functional osteoblasts, and are devoid of minera-
lised bone or hypertrophic cartilage [16]. Moreover,
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Figure 2 Relative expression levels of genes related to cell signalling in C2C12 cells treated with rhBMP2 and rhBMP7. Cells were
seeded and grown for 24 h at which point the medium was replaced by DMEM containing 5% FCS in the presence or absence of rhBMP2 (200
ng/ml) or rhBMP7 (200 ng/ml). RNA was isolated 0, 4, 8, 12 and 24h after stimulation. Subsequently, expression levels were measured by
quantitative real time RT-PCR. The asterisks correspond to the statistical analysis (two-way ANOVA, Bonferroni test) between control and
treatment (*p < 0.05; **p < 0.01; ***p < 0.001).
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mutations in this gene result in cleidocranial dysplasia,
which is characterised by bone alterations [17]. BMP2
and Runx2 act synergistically, stimulating osteodifferen-
tiation both in vitro and in vivo [18]. Indeed, Runx2
phosphorylation, through MAPK activation by FGF2,
seems to be important for the induction of osteocalcin
expression [19]. Therefore, the importance of Runx2 in
osteoblast differentiation and bone formation is clear: it
represents a hub gene in bone formation by regulating
osteoblast genes (Figure 4), along with the fact that this
gene is differentially expressed in C2C12 cells treated
with rhBMP2 and rhBMP7 (Figure 1), conferring greater
confidence with respect to the other genes selected in
this study.
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Figure 3 Relative expression levels of genes related to the extracellular matrix in C2C12 cells treated with rhBMP2 and rhBMP7. Cells
were seeded and grown for 24 h at which point the medium was replaced by DMEM containing 5% FCS in the presence or absence of rhBMP2
(200 ng/ml) or rhBMP7 (200 ng/ml). RNA was isolated 0, 4, 8, 12 and 24h after stimulation. Subsequently, expression levels were measured by
quantitative real time RT-PCR. The asterisks correspond to the statistical analysis (two-way ANOVA, Bonferroni test) between control and
treatment (*p < 0.05; **p < 0.01; ***p < 0.001).
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Id1, Id2 and Id3
The Id1, Id2 and Id3 genes were induced by treatment
of C2C12 cells with both rhBMPs (Figure 1). Id genes
encode proteins called ID (inhibitor of DNA binding), a
group of proteins which belong to the basic helix-loop-
helix (bHLH) family, but lack the basic region, which is
important in DNA binding and transcriptional activa-
tion. Evidence is available showing that Id1 forms het-
erodimers with E12/E47 and prevents MyoD from
forming complexes with E12/E47 in myoblasts [20,21].
Figure 4 Network of upregulated genes in C2C12 cells treated with rhBMP2 and rhBMP7 using the STRING 9.0 pathway analyzer.
STRING 9.0 is a database of known and predicted protein interactions. The interactions may be physically direct or indirect (functional). The list
of protein names are inserted as input and the organism to be analyzed is selected in a user-friendly web-browser interface. The network,
composed of the uploaded proteins, is constructed based on four different sources: genomic context, high-throughput experiments, co-
expression and scientific reports (http://string-db.org/). The upregulated genes found in each group (C2C12 cells treated with rhBMP7 or rhBMP2)
were matched and classified according to a pre-described interaction (activation, repression, or predicted interaction). The circles represent the
genes and the blue edges represent the interaction between them. The edges are based on proteins being co-mentioned in scientific
publications as well as their association in curated databases. The edge thickness is directly proportional to the degree of evidence available,
with lack of evidence for interactions in the literature being represented as no edges among the genes. Runx2: Runt Related Transcription factor
2; Dlx1/2/5: Distal-less homeobox 1/2 and 5;Id1/2/3: Inhibitor of DNA binding 1/2 and 3; Sp7, an alternative name for Osterix: Transcription factor
Sp7; Hoxc8: Homeobox protein Hox-C8; Fkhr1: Forkhead protein FKHR1; Glis1/3: Gli homologous protein 1; Cfdp1: Craniofacial development
protein 1; Lrp6: Low-density lipoprotein receptor-related protein 6; Segment polarity protein dishevelled homolog DVL-1; Ecsit: Evolutionarily
conserved signaling intermediate in the Toll pathway, mitochondrial; PKCd: Protein kinase C, delta type; Ltbp2: Latent-transforming growth factor
beta-binding protein 2; Grn: Granulin; BMP1: Bone Morphogenetic Protein 1; Plod1: Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1; Postn:
Periostin; Htra1: Serine protease HTRA1; Kazald1: Kazal-type serine protease inhibitor domain-containing protein 1 (IGFBP-rP10); Wnt3a: Protein
Wnt-3a; Dkk1: Dickkopf-related protein 1 and Ctnn1b: Catenin beta-1.
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The Id proteins are targets for BMP family members,
particularly for BMP2 [22,23]. Interestingly, a Smad
phosphatase, named C-terminal domain phosphatase
(SCP1) inhibited the activation of Id1, Id2 and Id3,
impairing osteoblastic differentiation in C2C12 cells
[24]. These effects on Id genes expression were only
described for cells treated with BMP2, as no report is
yet available for BMP7-treated cells. Together, the
results we present here and those of others [21] indicate
that these Id genes are, in fact, activated during osteo-
blastic differentiation upon treatment with both
rhBMP2 and rhBMP7.
Dlx1, Dlx2 and Dlx5
Treatment with rhBMP2 and rhBMP7 induced the
homeobox gene family related to the distal-less (Dll)
gene of Drosophila (Dlx1, Dlx2 and Dlx5 genes, Figure
1) [25]. The Dlx genes control the expression of various
genes involved in the development of invertebrates and
vertebrates. In mammals, they are expressed in the ner-
vous system derived from the neural crest and brachial
arches, participating in the development of the brain,
craniofacial structures and the axial and appendicular
skeleton [25]. In view of these characteristics, the Dlx1,
Dlx2 and Dlx5 transcription factors may be very impor-
tant during osteoblastic differentiation. Particularly, evi-
dence is available indicating that Dlx5 is a direct target
for BMPs. During osteogenic transdifferentiation of
C2C12 cells, it has been demonstrated that Dlx5 regu-
lates the expression of Runx2 in cells treated with
rhBMP2, but not with TGFb1 [26] (interaction between
Runx2 and Dlx5, as shown in Figure 4). This, together
with the ability of BMP2 to induce the expression of
alkaline phosphatase (ALP) and Osx in Runx2-/- knock-
out mouse cells, could represent an additional pathway
by which Dlx5 modulates the expression of Runx2 and
Osx. Dlx5, but not Runx2, is essential for the expression
of Osx in cells treated with BMP2 [15], indicating that
Dlx5 regulates the expression of Osx independently of
Runx2. These data are consistent with the Dlx5 gene
expression profile obtained here for both rhBMP treat-
ments, so it is likely that Dlx1 and Dlx2 could also par-
ticipate in this or similar mechanisms.
Osx
Osx, a zinc finger-containing transcription factor, was
the gene with the greatest relative induction level upon
treatment of C2C12 cells with rhBMPs. This gene is
expressed in all bones, and Osx-/- knock-out mice lack
mineralised bone [27]. It has been suggested that Osx
acts in the terminal differentiation of osteoblasts to
operate the distinction between chondrogenic and
osteogenic pathways while Runx2 acts upstream, in the
commitment of mesenchymal cells to chondrocytes or
osteoblasts [28]. Osx regulates the expression of impor-
tant genes in bone, such as those coding for bone
sialoprotein (BSP), osteocalcin, osteonectin and osteopon-
tin [29]. As mentioned above, Dlx5 regulates the expres-
sion of Osx (also known as Sp7, node in Figure 4).
Interestingly, confirming data from the literature on the
expression profile of Dlx2 and Dlx5, it may be noted
that the Osx transcript significantly increased between
12 and 24 h, which may be related to the increase in
Dlx2 and Dlx5 expression during the same period of
time, revealing that although Osx first requires Dlx5,
later on, Dlx2 could also be important for resuming
osteodifferentiation (Figure 1).
Fkhr1
The Fkhr1 transcription factor, which we found to be
differentially expressed in C2C12 cells, is able to stimu-
late alkaline phosphatase gene expression, increasing its
activity. This protein and the family of factors to which
it belongs are involved in regulating processes such as
the cell cycle, apoptosis, glucose metabolism, cell differ-
entiation and embryogenesis [30]. Recently, a study
demonstrated that Fkhr1 is involved in osteoblastic dif-
ferentiation of MC3T3-E1 cells, since Fkhr1 knockdown
cells failed to perform matrix mineralisation, and immu-
noprecipitation assays suggest an interaction between
Fkhr1 and the RunX2 promoter [31]. Moreover,
increased Fkhr1 expression and ALP activity were
detected six days after treatment of hMSC (human mar-
row cells) with BMP2 [32]. We found that the expres-
sion fell to basal levels 24 h after treatment in both
BMP2 and BMP7-treated cells (Figure 1), while the ALP
activity began to gradually increase after 48 h of treat-
ment (data not shown). A few explanations for this may
be envisaged, namely: a) ALP expression is activated by
other transcription factors, such as Runx2 and Dlx5; b)
the decrease in the level of Fkhr1 transcripts does not
mean that the same occurs at the protein level; 3) the
Fkhr1 transcript level could increase again 24 h after
stimulation.
Hoxc8
Hoxc8 belongs to the family of conserved Hox genes,
which are expressed in the neural tube, cartilage and
bone [33]. Hoxc8 binds to the osteopontin (Spp1) and
osteoprogeterin (OPG) promoters, acting as a transcrip-
tional repressor. We showed that Hoxc8 was induced by
rhBMP2 between 4 and 24 h, and by rhBMP7 between
12 and 24 h (Figure 1). Despite the role of Hoxc8 in the
inhibition of osteoblastogenesis, evidenced by stimula-
tion of Smad6 expression in BMP2-treated cells [34], its
expression could be explained by a negative feedback
loop, regulating the activated Smads, similar to what
occurs in in vivo bone metabolism. Recently, it has been
reported that BMP2 regulates the expression of miR-
199a* microRNA, which, in turn, downregulates the
expression of Smad1. Therefore, the increased expres-
sion of Hoxc8, caused by BMPs, may be related an
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inhibition in Smad1 function (Figure 4) additionally
caused by miRNA-199a* [35]. It is interesting to note
that a high fold-induction of Hoxc8 was obtained in
rhBMP2-treated cells, whereas only slightly increased
expression was observed for rhBMP7-treated cells, when
compared to the control. This suggests that the differ-
ence in receptor binding between each BMP implies not
only common intracellular messengers, but also activa-
tion of different intracellular proteins which may be
responsible for this difference in expression levels.
Glis1 and Glis3
rhBMP2 and rhBMP7 also induced the Glis1 and Glis3
(Gli similar) genes (Figure 1), both of which code for
transcription factors belonging to the family of Krüppel-
like zinc finger proteins [36]. Glis1 and Glis3 contain
five Cys2-His2-type zinc-finger motifs which exhibit
high homology with those of Gli. However, Glis and Gli
proteins exhibit low sequence homology outside their
zinc-finger domain. Deletion analysis demonstrated that
Glis proteins contain both repressor and activator
domains, suggesting that they may function as positive,
as well as negative, regulators of gene transcription, and
evidence is available suggesting that Glis3 participates in
various stages of organogenesis [15]. The expression of
Glis1 has been detected during embryogenesis in cranio-
facial regions, brachial arches and kidney somites [36].
Glis3 has recently been shown to operate synergistically
with BMP2 and Shh in osteoblastic differentiation of
C3H10T1/2 mesenchymal cells, inducing the expression
of FGF18 [37], indicating that this factor may be impor-
tant during osteodifferentiation. Here, we show that
Glis1 expression increased upon treatment with rhBMPs
between 4 and 24 h, (Figure 1), resulting in a greater
transcript level increase in cells treated with rhBMP2.
To date, no evidence is available relating Glis1 with
osteodifferentiation induced by BMPs, but its role could
possibly be similar to that of Glis3, due to the high
homology between these genes. Undoubtedly, in view of
the scarce knowledge on the potential role of these tran-
scription factors in osteoblastic differentiation, future
studies should be directed to clarify their importance in
this cellular process.
Cfdp1
Cfdp1 expression was induced earlier by rhBMP2 (4-24
h) when compared to rhBMP7 (12-24 h) (Figure 1).
Cfdp1 has been detected in some tissues, particularly in
teeth and bones. This protein contains a domain called
BCNT-c (Bucentaur), which displays homology to one
of the proteins constituting the yeast Swr1 complex,
which modifies the chromatin state, thereby transcrip-
tionally regulating several genes. Cfdp1 was cloned from
a mouse library, and the equivalent region in the human
genome was found to be associated with craniofacial
syndromes. The specific function of Cfdp1 is unknown,
but it is presumed to be important during embryogen-
esis [38]. Evidence is available indicating that Cfdp1 par-
ticipates in tooth development [39] and could play a
similar function during bone formation. Further investi-
gation is necessary to establish the actual role of Cfdp1
in osteogenesis.
Genes involved in cellular signalling
BMP-activated cell signalling involves the Smad proteins
[40]. Interestingly, our analysis of microarrays generated
four candidate genes which participate in other path-
ways, such as Wnt (canonical and non-canonical) and
Toll, indicating that these pathways could interact and
take part during osteoblastic differentiation. Figure 2
shows a similar expression profile for the Lrp6 and Dvl1
genes upon treatment with rhBMPs. These genes parti-
cipate in canonical Wnt signalling [41], with evidence
showing their relationship with osteogenesis [42,43].
Lrp6-/- knock-out mice display reduced vertebral trabe-
cular bone volume (TBV), demonstrating the impor-
tance of LRP6 in bone formation [44]. Moreover, it has
been shown that this co-receptor participates in somito-
genesis and osteogenesis [45]. Dvl1 participates, along
with other proteins, in the stabilisation of b-catenin,
thus inhibiting the activity of GSK3b kinase [46]. Some
data suggest that Dvl1 and? other components of Wnt
signalling are activated during bone regeneration and
that, particularly, the Dvl isoforms (1, 2 and 3) could be
important in the proliferation and differentiation of
chondrocytes [41]. The increased expression of Lrp6
and Dvl1, observed here, could mean that treatment of
C2C12 cells with rhBMPs leads to increased expression
of genes related to the signalling, thereby intensifying
the effect initially induced by BMPs. In this respect,
using C2C12 and C3H10T1/2 cells, a synergy has been
shown between b-catenin and BMP2 to promote osteo-
differentiation [47]. Also, it is possible that b-catenin,
along with TCF1, may increase Runx2 expression [48].
Ecsit
Increased expression of Ecsit was observed between 4
and 12 h of treating C2C12 cells with BMPs (Figure
2). Ecsit participates in the Toll pathway, which regu-
lates pro-inflammatory genes. Ecsit also participates in
BMP/Smad signalling, interacting with Smad1 and
Smad4 and activating the expression of Tlx2 and other
genes [49]. During embryogenesis, the Toll and BMP/
Smad pathways interact for dorsoventral axis forma-
tion. On the other hand, Ecsit-/- knock-out mice dis-
played alterations in epiblast and mesoderm formation,
dying at embryonic day 7.5 (E7.5) [50]. The exact
mechanism by which this protein could be involved in
osteoblastic differentiation is unknown, requiring
further analysis, but its interaction with the Smad1/4
proteins, and possibly with RunX2 (Figure 4), which
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are both known to be involved in osteodifferentiation,
suggests that Ecsit is part of this cellular process, mak-
ing it likely that the Toll pathway could also be
involved in osteoblast differentiation.
PKCδ
Another gene associated with cell signalling, which we
found to be induced by BMPs and validated by RT-
qPCR, is PKCδ. The enzyme encoded by this gene
belongs to the protein kinase C (PKC) family, which
consists of 11 members [51]. Recently, using ST2 cells,
it has been shown that PKCδ activation is induced by
Wnt3a through the canonical pathway, and also by the
non-canonical Wnt pathway through Wnt7b in ST2
and C3H10T1/2 cells. These results indicate the invol-
vement of PKCδ during osteodifferentiation in these
cells, which could indicate that Wnt7b and PKCδ regu-
late the onset of Osx expression [52]. Another study
showed activation of the PKC pathway in MC3T3 and
C2C12 cells treated with FGF2, with PKCδ being one
of the key isoforms involved in FGF2-stimulated
Runx2 expression [15].
Proteins associated with the extracellular matrix
Osteoblasts secrete an extracellular matrix (ECM)
formed by various proteins, some of which directly par-
ticipate in mineralisation of the osteomatrix [19]. For
this reason, seven genes representing secreted proteins,
with the exception of Plod1, an intracellular enzyme,
were analysed. Figure 3 shows that the expression of
Ltbp2 increased upon treatment with rhBMPs. This pro-
tein is part of the latent TGFb complex, placing it in
the ECM. TGFb is activated upon removal from this
complex [53]. A possible relationship between Ltbp2,
TGFb and rhBMPs induced transdifferentiation of
C2C12 cells, which may represent, in part, what occurs
in bone metabolism, since TGFb participates in osteo-
clastogenesis, regulating the expression of osteoprote-
gerin (OPG) and the receptor activator of the NF-B
ligand (RANKL) in osteoblasts and, also, the receptor
activator of NF-B (RANK) in osteoclasts. Therefore, it
is important that TGFb be released from this latent
complex in order to exert its effect [54].
Grn, Postn and Plod1
Coincidentally, our results show that Grn, Postn, Plod1
and BMP1 were induced between 12 and 24 h after
treatment with rhBMPs. Grn (granulins) are proteins
involved in inflammation, repair and remodeling of
injured tissues. Although the function of Grn in osteo-
differentiation is unknown, it has an osteoclastic origin
[55]. Possibly, Grn could participate in bone remodeling,
but, obviously, further studies should be carried out to
investigate, in more detail, the functions of these pro-
teins in bone tissue. Postn was isolated from osteoblasts
as a specific factor, shown to be preferentially expressed
in the periosteum. The function of Postn is related to
recruitment, adhesion and extension of osteoblasts [13].
Interestingly, the expression of Postn began to increase
after 12 h and progressively increased up to 24 h, indi-
cating that the cells were beginning to display character-
istics found in differentiated osteoblasts. Plod1 is not
secreted, as it is an intracellular enzyme involved in
lysine hydroxylation of type I collagen, the main protein
present in bone. In agreement with our results,
increased expression of Plod1 was obtained during dif-
ferentiation of bone marrow stromal cells (BMSCs) and
normal skin fibroblasts (NSFs) [56]. Therefore, increased
expression of Plod1 during osteoblastic differentiation
implicates a stabilisation of collagen type I, which may
indicate the beginning of extracellular matrix formation
in osteoblasts. BMP1 is an important metalloproteinase
in morphogenetic processes in several species. During
ECM formation, BMP1 performs the processing of pre-
cursor molecules, rendering them into functional ECM
components. The substrates of BMP1 include pro-col-
lagens, proteoglycan precursors and proteins associated
with ECM mineralisation of bone and teeth. Some sub-
strates are members of the latent complex of TGFb
family members, such as TGFb1, BMP2 and BMP4 [57].
Recent evidence has shown that BMP1 cleaves LTBP
molecules, releasing the latent complex of TGFb1-LAP
from the ECM; subsequently, the LAP protein (latency-
associated peptide) is cleaved by another protease,
resulting in the activation of TGFb [58]. Our results
show the same expression profile for LTBP2 and BMP1
upon induction by rhBMP2 and rhBMP7, associating
them with ECM formation and osteoclastogenesis and
indicating that both proteins participate in the regula-
tion of TGFb1, which is known to be important in such
processes.
Htra1
Htra1 is a family of serine peptidases. It has recently
been demonstrated that over-expression of Htra1 during
osteoblastic differentiation of 2T3 cells causes inhibition
of ECM mineralisation, suggesting that this may be due
to one of three different causes: a) Htra1 modulates the
expression of specific osteoblast genes; b) Htra1 alters
the activity TGFb/BMP pathway; or c) Htra1 cleaves
proteins that regulate ECM differentiation and/or
mineralisation [59]. Inhibition of ECM mineralisation in
these cells by Htra1 could represent a mechanism to
control the speed at which the mineralisation process
occurs, but more evidence is required to confirm this
hypothesis. The possible effect of Htra1 in the ECM
mineralisation of C2C12 and/or other pre-osteoblastic
cells should be further examined.
IGFBP-rP10
IGFBP-rP10 is a member of the insulin growth factor
binding protein (IGFBP) family. These proteins are
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involved in the growth and maturation of various tissues
through their association with ECM proteins, mediating
the access, migration and cellular chemotaxis. IGFBPs
bind to integrins, possibly modulating the TGFb and
Wnt pathways. According to our results, rhBMP2 is
able to induce the expression of IGFBP-rP10 in different
cell lines, in addition to C2C12 cells, rendering it very
likely that IGFBP-rP10 actively participates in the differ-
entiation and proliferation of osteoblasts during bone
formation and bone regeneration [60]. The mechanism
by which this protein is induced by BMP2 and BMP7
and how it is involved in these cellular processes repre-
sents an interesting challenge which should be faced in
the future.
In summary, using DNA microarrays, we have
described the pattern of expression of genes which are
induced during transdifferentiation of pre-myoblastic
C2C12 cells during 24 h of treatment with rhBMP2 and
rhBMP7. A total of 1,318 genes were found to be
induced by both rhBMPs which could be involved in
osteoblastic differentiation, twenty-four of which were
confirmed through RT-qPCR after 4, 8, 12 and 24h of
treatment, resulting in 13 transcription-related genes
(Runx2, Dlx1, Dlx2, Dlx5, Id1, Id2, Id3, Fkhr1, Osx,
Hoxc8, Glis1, Glis3 and Cfdp1) which were induced
between 4 and 24 h after treatment. Four of the genes
identified (Lrp6, Dvl1, Ecsit and PKCδ) are implicated in
cell signalling, displaying a more heterogeneous pattern
of expression, and seven are ECM-related genes (Ltbp2,
Grn, Postn, Plod1, BMP1, Htra1 and IGFBP-rP10),
which were preferentially activated after 12 h of treat-
ment. Our results revealed some genes which were
already known to be activated by BMP2. However, we
found that many of them were also upregulated by
treatment with rhBMP7, thus representing a novel sub-
set of genes related with BMP7-induced differentiation
of precursor cells into osteoblasts: Hoxc8, Glis1, Glis3,
Ecsit, PKCd, LrP6, Dvl1, Grn, BMP1, Ltbp2, Plod1,
Htra1 and IGFBP-rP10. Fifteen genes were upregulated
in the early period (during the first 12 h) while nine
genes were upregulated at a later period (between 12
and 24 h). Among the downregulated genes, MyoD
showed a decreased abundance in mRNA relative
expression (data not shown), which is explained by the
fact that, in the absence of BMPs, this muscular satellite
cell line would be programmed to differentiate into
myoblasts [20]. Currently, we do not know whether the
increased expression of genes at later stages was merely
due to the indirect downstream effects of BMP/SMAD
signalling as a result of earlier gene (for example, Ids)
expression changes. Subsequent studies may elucidate
whether the products of these upregulated early genes
are responsible for inducing the expression of later
genes.
The network analysis of the upregulated genes showed
a high connectivity for most of them, with some hubs
being distinguished by having six interactions or more,
namely a) RunX2, a well-known player in osteoblasto-
genesis; b) Smad 1, an intracellular transducer of BMP
proteins; c) Akt1, a kinase recently found to induce Osx
transcription, showing evidence for crosstalk between
BMP- Smads and PI 3-kinase/Akt signalling [61]; and d)
the Dvl1/Ctnnb1 (b-catenin 1) axis, both of which
belong to the Wnt pathway. b-catenin 1 is described to
be activated upon BMP2 treatment in C3H10T1/2 cells,
playing a role in the Wnt-independent pathway mechan-
ism of bone differentiation [62]. These data suggest that
the abovementioned genes, despite belonging to distinct
pathways, are related to each other in BMP-driven
osteoblastogenesis.
It is noteworthy that the results presented here apply to
this model of C2C12 osteoblastic differentiation, which
may or may not be identical to that of other types of
osteoblastic progenitors, due to the availability of BMP
receptors on their surface and on how capable they are of
triggering intracellular downstream pathways.
BMP2 and BMP7 both signal through the ALK2 and
ALK3 receptors; however, BMP7 predominantly signals
via the ALK2 receptor. This alternative signalling
mechanism might account for some of the differences in
the level of gene expression reported following BMP2
and BMP7 stimulation. The fact that there are differ-
ences in the levels of gene expression induced by BMP2
and BMP7 was proven, in vivo, to be due to different
biological steps of activation of differentiation. Thus,
while BMP2 plays a role in the early stages of osteoblas-
tic differentiation, BMP7 participation is more delayed,
sustaining osteoblast maturation, rather than triggering
the initial differentiation signal [63]. Another possibility
is the existence of unknown receptors or other pathways
directly modulating the action of each BMP, as already
described for MAPK and/or indirectly, as described by
the Wnt pathway (the node representing the Wnt3a
protein was found to interact with Lrp6, Ctnnb1, Dvl1,
Dkk1 and Dlx5 in Figure 4) [64]. Therefore, subsequent
studies should address whether BMP7 signalling through
the ALK2 receptor may generate differences in gene
expression for Id2 and Dvl1 (and other genes), as com-
pared with BMP2 signalling.
Our findings are relevant to better understanding the
molecular basis for BMP-induced osteogenesis during
development and the bone healing processes; however,
further studies are still required to investigate the intri-
cate network of pathways triggered by these cytokines.
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